Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Masato TakahashiEriko TokunagaJoji MoriYoshinori TanizawaJan-Stefan van der WaltTsutomu KawaguchiMatthew P GoetzMasakazu ToiPublished in: Breast cancer (Tokyo, Japan) (2021)
NCT02246621; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02246621 .